Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Eslicarbazepine Acetate Sources
NCT02284880Phase 1Completed
- Sponsor
- BIAL
- Start
- Oct 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of eslicarbazepine acetate in epilepsy (2 arms), sponsored by BIAL. Primary endpoints: Maximum Plasma Concentration, Time of Occurrence of Cmax and 1 more. Started Oct 2010; status: completed.
02
Drugs
eslicarbazepine acetate
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02284880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02284880.